| 臺大學術典藏 |
2021-09-01T01:54:11Z |
Recent advances in the treatment of metastatic colorectal cancer in Taiwan
|
Lin Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T01:53:57Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T01:53:55Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:54Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 朝陽科技大學 |
2021-09 |
Fuzzy tree classification system for fault diagnosis on Ion implanter
|
Horng, S C; Lin, Y L; 洪士程; 林昱伶 |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:50Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
Chen K.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:43Z |
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study
|
Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:24Z |
CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
|
Chen K.-H.; Lin L.-I.; Tseng L.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-20T08:50:11Z |
Bacterial diversity among four healthcare-associated institutes in Taiwan
|
Chen C.-H.; Lin Y.-L.; Chen K.-H.; Chen W.-P.; Chen Z.-F.; HAN-YUEH KUO; Hung H.-F.; Tang C.Y.; Liou M.-L. |
| 臺大學術典藏 |
2021-08-20T02:45:42Z |
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study
|
KUO-HSING CHEN; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-20T02:45:42Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
KUO-HSING CHEN; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-20T02:45:41Z |
CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
|
KUO-HSING CHEN; Lin L.-I.; Tseng L.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:23Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; YANG SHIH-HUNG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-11T03:46:42Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:39Z |
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study
|
Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN; Lai M.-S.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-10T03:53:01Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-05T02:40:12Z |
Fabrication and modification of forward osmosis membranes by using graphene oxide for dye rejection and sludge concentration
|
Lin C.-S;Tung K.-L;Lin Y.-L;Dong C.-D;Chen C.-W;Wu C.-H.; Lin C.-S; Tung K.-L; Lin Y.-L; Dong C.-D; Chen C.-W; Wu C.-H.; KUO-LUN TUNG |
| 臺大學術典藏 |
2021-07-26T10:01:58Z |
Curcumin and freshwater clam extracts alleviate the progression of osteoarthritis by reducing synovial inflammation and allowing cartilage regeneration
|
Ke C.-H;Hsu C.-H;Lin Y.-L;Huang W.-H;Weng H.-P;Ke Y.-T;Lin C.-S.; Ke C.-H; Hsu C.-H; Lin Y.-L; Huang W.-H; Weng H.-P; Ke Y.-T; Lin C.-S.; WEI-HSIANG HUANG |
| 臺大學術典藏 |
2021-07-26T10:01:45Z |
Ameliorative effects of functional crude-chalaza hydrolysates on the hepatosteatosis development induced by a high-fat diet
|
Chen J.-W;Lin Y.-L;Samuel Wu Y.-H;Wang S.-Y;Chou C.-H;Chen Y.-C.; Chen J.-W; Lin Y.-L; Samuel Wu Y.-H; Wang S.-Y; Chou C.-H; Chen Y.-C.; CHUNG-HSI CHOU |
| 臺大學術典藏 |
2021-07-26T10:01:21Z |
Ameliorative effects of functional crude-chalaza hydrolysates on the hepatosteatosis development induced by a high-fat diet
|
Chen J.-W;Lin Y.-L;Samuel Wu Y.-H;Wang S.-Y;Chou C.-H;Chen Y.-C.; Chen J.-W; Lin Y.-L; Samuel Wu Y.-H; Wang S.-Y; Chou C.-H; Chen Y.-C.; YI-CHEN CHEN |
| 臺大學術典藏 |
2021-07-26T10:01:21Z |
Ameliorative effects of functional chalaza hydrolysates prepared from protease-A digestion on cognitive dysfunction and brain oxidative damages
|
Chan C.-J;Tseng J.-K;Wang S.-Y;Lin Y.-L;Samuel Wu Y.-H;Chen J.-W;Chen Y.-C.; Chan C.-J; Tseng J.-K; Wang S.-Y; Lin Y.-L; Samuel Wu Y.-H; Chen J.-W; Chen Y.-C.; YI-CHEN CHEN |
| 臺大學術典藏 |
2021-07-26T10:01:20Z |
Cardiac protection of functional chicken-liver hydrolysates on the high-fat diet induced cardio-renal damages via sustaining autophagy homeostasis
|
Wu Y.-H.S;Lin Y.-L;Huang C;Chiu C.-H;Nakthong S;Chen Y.-C.; Wu Y.-H.S; Lin Y.-L; Huang C; Chiu C.-H; Nakthong S; Chen Y.-C.; YI-CHEN CHEN |
